NASDAQ:NTRA - Natera Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.42 +0.61 (+4.12 %) (As of 11/22/2018 06:00 AM ET)Previous Close$14.81Today's Range$14.63 - $15.6952-Week Range$8.60 - $29.62Volume393,181 shsAverage Volume447,323 shsMarket Capitalization$957.03 millionP/E Ratio-6.43Dividend YieldN/ABeta2.11 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. Natera, Inc. has collaboration partnership with Fox Chase Cancer Center to assess customized circulating tumor DNA assay for recurrence monitoring of kidney cancer; and clinical trial collaboration with Neon Therapeutics, Inc. to assess the treatment response to personal cancer vaccine. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California. Receive NTRA News and Ratings via Email Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTRA Previous Symbol CUSIPN/A Webwww.natera.com Phone650-249-9090 Debt Debt-to-Equity Ratio1.30 Current Ratio2.44 Quick Ratio2.32 Price-To-Earnings Trailing P/E Ratio-6.43 Forward P/E Ratio-7.31 P/E GrowthN/A Sales & Book Value Annual Sales$210.94 million Price / Sales4.52 Cash FlowN/A Price / CashN/A Book Value$0.92 per share Price / Book16.76 Profitability EPS (Most Recent Fiscal Year)($2.40) Net Income$-136,310,000.00 Net Margins-58.00% Return on Equity-2,569.52% Return on Assets-60.02% Miscellaneous Employees893 Outstanding Shares61,820,000Market Cap$957.03 million OptionableOptionable Natera (NASDAQ:NTRA) Frequently Asked Questions What is Natera's stock symbol? Natera trades on the NASDAQ under the ticker symbol "NTRA." How were Natera's earnings last quarter? Natera Inc (NASDAQ:NTRA) announced its quarterly earnings results on Thursday, November, 8th. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.03. The medical research company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $66.42 million. Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. The business's revenue was up 16.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.51) EPS. View Natera's Earnings History. When is Natera's next earnings date? Natera is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Natera. What guidance has Natera issued on next quarter's earnings? Natera updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $263.2 million. What price target have analysts set for NTRA? 7 brokerages have issued 1 year target prices for Natera's shares. Their forecasts range from $20.00 to $41.00. On average, they anticipate Natera's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 88.1% from the stock's current price. View Analyst Price Targets for Natera. What is the consensus analysts' recommendation for Natera? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera. Has Natera been receiving favorable news coverage? Media coverage about NTRA stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Natera earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Natera's key competitors? Some companies that are related to Natera include Guardant Health (GH), Genomic Health (GHDX), CareDx (CDNA), InVitae (NVTA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI), Cancer Genetics (CGIX) and OpGen (OPGN). Who are Natera's key executives? Natera's management team includes the folowing people: Dr. Matthew Rabinowitz, Co-Founder, CEO, Pres & Chairman (Age 45)Mr. Michael Brophy, Chief Financial Officer (Age 38)Mr. Steve Chapman, Chief Operating Officer (Age 39)Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 45)Mr. Daniel Rabinowitz L.L.M., LL.M., Sec. & Gen. Counsel When did Natera IPO? (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's stock is owned by many different of retail and institutional investors. Top institutional investors include Jennison Associates LLC (5.98%), Capital World Investors (5.28%), BlackRock Inc. (4.57%), FMR LLC (4.09%), Macquarie Group Ltd. (3.26%) and Renaissance Technologies LLC (2.51%). Company insiders that own Natera stock include Claremont Creek Partners Fund, Herm Rosenman, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera. Which major investors are selling Natera stock? NTRA stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Rubric Capital Management LP, First Manhattan Co., Broadview Advisors LLC, Kornitzer Capital Management Inc. KS, EAM Investors LLC, Essex Investment Management Co. LLC and Capital Impact Advisors LLC. Company insiders that have sold Natera company stock in the last year include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera. Which major investors are buying Natera stock? NTRA stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, Renaissance Technologies LLC, BlackRock Inc., Credit Suisse AG, Harvard Management Co. Inc., Peregrine Capital Management LLC and Regents of The University of California. View Insider Buying and Selling for Natera. How do I buy shares of Natera? Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Natera's stock price today? One share of NTRA stock can currently be purchased for approximately $15.42. How big of a company is Natera? Natera has a market capitalization of $957.03 million and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Natera employs 893 workers across the globe. What is Natera's official website? The official website for Natera is http://www.natera.com. How can I contact Natera? Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090. MarketBeat Community Rating for Natera (NASDAQ NTRA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 240 (Vote Outperform)Underperform Votes: 219 (Vote Underperform)Total Votes: 459MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/22/2018 by MarketBeat.com StaffFeatured Article: What is intrinsic value?